These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35367296)

  • 1. Diagnostic testing of eczematous dermatitis with incomplete response to dupilumab.
    Bai H; Murase EM; Ashbaugh AG; Botto NB; Murase JE
    J Am Acad Dermatol; 2022 Sep; 87(3):692-695. PubMed ID: 35367296
    [No Abstract]   [Full Text] [Related]  

  • 2. Comment on "Diagnostic testing of eczematous dermatitis with incomplete response to dupilumab".
    Cohen JM; Damsky W; Girardi M
    J Am Acad Dermatol; 2022 Dec; 87(6):e241-e242. PubMed ID: 35933070
    [No Abstract]   [Full Text] [Related]  

  • 3. Dupilumab use in dermatologic conditions beyond atopic dermatitis - a systematic review.
    Hendricks AJ; Yosipovitch G; Shi VY
    J Dermatolog Treat; 2021 Feb; 32(1):19-28. PubMed ID: 31693426
    [No Abstract]   [Full Text] [Related]  

  • 4. The impact of dupilumab on patch testing and the prevalence of comorbid allergic contact dermatitis in recalcitrant atopic dermatitis: A retrospective chart review.
    Raffi J; Suresh R; Botto N; Murase JE
    J Am Acad Dermatol; 2020 Jan; 82(1):132-138. PubMed ID: 31562940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of dupilumab in the management of idiopathic chronic eczematous eruption of aging.
    Shahriari N; Strober B; Shahriari M
    J Am Acad Dermatol; 2020 Nov; 83(5):1533-1535. PubMed ID: 32679275
    [No Abstract]   [Full Text] [Related]  

  • 6. Strategies for Successful Management of Severe Atopic Dermatitis.
    Brar KK; Nicol NH; Boguniewicz M
    J Allergy Clin Immunol Pract; 2019 Jan; 7(1):1-16. PubMed ID: 30598172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generalized eczematous dermatitis and pruritus responsive to dupilumab in a patient with immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome.
    Maher MC; Hall EM; Horii KA
    Pediatr Dermatol; 2021 Sep; 38(5):1370-1371. PubMed ID: 34272772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A possible role for dupilumab (Dupixent) in the management of idiopathic chronic eczematous eruption of aging.
    Brummer GC; Wang LT; Sontheimer RD
    Dermatol Online J; 2018 Feb; 24(2):. PubMed ID: 29630150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dupilumab for severe generalized eczematous eruption complicating common variable immunodeficiency.
    Votquenne N; Dupire G; Michel O; Ben Said B
    Eur J Dermatol; 2021 Feb; 31(1):93-94. PubMed ID: 33586652
    [No Abstract]   [Full Text] [Related]  

  • 10. Superimposed linear atopic dermatitis treated with dupilumab.
    Leszczynska MA; Trainor MA; Henkel E; Keeling BH; Diaz LZ
    Pediatr Dermatol; 2021 Sep; 38(5):1377-1378. PubMed ID: 34272754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Machine learning analysis of pretreatment skin biopsies predicts nonresponse to dupilumab in patients with eczematous dermatitis.
    Murphy MJ; Hwang E; Singh K; Lee T; Cohen JM; Damsky W
    Br J Dermatol; 2023 Dec; 190(1):132-134. PubMed ID: 37818837
    [No Abstract]   [Full Text] [Related]  

  • 12. Variable impact of dupilumab on patch testing results and allergic contact dermatitis in adults with atopic dermatitis.
    Stout M; Silverberg JI
    J Am Acad Dermatol; 2019 Jul; 81(1):157-162. PubMed ID: 30885752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three cases of non-atopic hyperkeratotic hand eczema treated with dupilumab.
    Loman L; Diercks GFH; Schuttelaar MLA
    Contact Dermatitis; 2021 Feb; 84(2):124-127. PubMed ID: 32864776
    [No Abstract]   [Full Text] [Related]  

  • 14. Dupilumab after the 2017 approval for the treatment of atopic dermatitis: what's new and what's next?
    van der Schaft J; Thijs JL; de Bruin-Weller MS; Balak DMW
    Curr Opin Allergy Clin Immunol; 2019 Aug; 19(4):341-349. PubMed ID: 31145194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allergic contact dermatitis to Compositae: A possible cause of dupilumab-associated facial and neck dermatitis in atopic dermatitis patients?
    Napolitano M; Fabbrocini G; Patruno C
    Contact Dermatitis; 2021 Oct; 85(4):473-474. PubMed ID: 33988858
    [No Abstract]   [Full Text] [Related]  

  • 16. The long-term effect of dupilumab on chronic hand eczema in patients with moderate to severe atopic dermatitis-52 week results from the Dutch BioDay Registry.
    Voorberg AN; Romeijn GLE; de Bruin-Weller MS; Schuttelaar MLA
    Contact Dermatitis; 2022 Aug; 87(2):185-191. PubMed ID: 35279856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dupilumab for Allergic Contact Dermatitis: An Overview of Its Use and Impact on Patch Testing.
    Johnson H; Adler BL; Yu J
    Cutis; 2022 May; 109(5):265-267. PubMed ID: 35856769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dupilumab: A Review of Present Indications and Off-Label Uses.
    Muñoz-Bellido FJ; Moreno E; Dávila I
    J Investig Allergol Clin Immunol; 2022 Apr; 32(2):97-115. PubMed ID: 33661102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eczematous reaction to ixekizumab successfully treated with dupilumab.
    Napolitano M; Gallo L; Patruno C; Fabbrocini G; Megna M
    Dermatol Ther; 2020 Mar; 33(2):e13218. PubMed ID: 31912951
    [No Abstract]   [Full Text] [Related]  

  • 20. Characterization of Residual Facial Dermatitis during Dupilumab Therapy: A Retrospective Chart Review to Delineate the Potential Role of Expanded Series Patch Testing.
    Ashbaugh AG; Murase EM; Raffi J; Botto N; Murase JE
    Dermatitis; 2022 Jan-Feb 01; 33(1):51-61. PubMed ID: 35029349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.